News

NexBio in collaboration with scientists at the centers for disease control and prevention (CDC), has published two studies that suggests DAS181 (Fludase) may play a potentially important role

Graceway Pharmaceuticals (Graceway) has acquired the worldwide license, including related regulatory filings and intellectual properties from Gilead Sciences, to its’s investigational molecule, GS 9191, for topical use. GS

Intarcia has presented data for ITCA 650 (DUROS continuous delivery of exenatide) program for the treatment of type 2 diabetes at the Ninth Annual Diabetes Technology Meeting in

Genetix Pharmaceuticals has launched its clinical program to treat Adrenoleukodystrophy (ALD). It is developing a gene therapy product in collaboration with Professor Patrick Aubourg and Doctor Nathalie Cartier

GlaxoSmithKline Biologicals (GSK) has received prequalification from the World Health Organization (WHO) for global use to Synflorix, pneumococcal conjugate vaccine. The WHO prequalification allows UN agencies to purchase

The topic for the Grand Challenge Grant is low cost diagnostics for global priory health conditions, which includes both malaria and tuberculosis. Clayton Hardman, CEO of Biomagnetics Diagnostics,

The randomised phase II trial treats patients with unresectable or metastatic soft tissue sarcoma in the front- and second-line setting. Patients are randomised either to doxorubicin (the only

Arkema has presented to its Balan facility’s trade union representatives a plan to shut-down a 30,000 ton PVC production unit on the site in order to strengthen the

PPD has completed its acquisition of Excel, a contract research organisation in China. The acquisition strengthens PPD’s full range of drug development services in the country and positions